Most Active Stocks to Focus: Yingli Green Energy Holding Co Ltd (ADR) (NYSE:YGE), POZEN Inc. (NASDAQ:POZN)

Active Stocks

Shares of Yingli Green Energy Holding Co Ltd (ADR) (NYSE:YGE), declined – 21.46% to $0.328, amid its last exchanging session.


Yingli Green Energy Holding Company Limited, together with its helpers, plans, creates, markets, makes, offers, and introduces photovoltaic (PV) items in the People’s Republic of China and universally.

Yingli Green Energy Holding Company Limited (YGE), one of the world’s driving sun powered board producers, as of late announced that its holding accomplice, Baoding Tianwei Yingli New Energy Company Limited, arrangements to rebuild the reimbursement arrangement for $157 million USD (1.0 billion RMB) of mid-term notes (“MTNs”) due on October 13, 2015.

Shares of POZEN Inc. (NASDAQ:POZN), declined – 17.39% to $5.70, amid its last exchanging session.

POZEN Inc., a pharmaceutical organization, creates items for the treatment of intense and interminable torment, and agony related conditions in the United States and universally. Its key PA item competitors involve PA32540 and PA8140 for optional avoidance of cardiovascular and cerebrovascular sickness in patients at danger for gastric ulcers, which have fulfilled clinical advancement in the United States.

POZEN Inc. (POZN), as of late announced that James P. Tursi, M.D. will be assigned Chief Medical Officer of POZEN, successful October 1, 2015. Dr. Tursi will answer to Adrian Adams, Chief Executive Officer of POZEN, and will be in charge of the oversight of the clinical operations, drug wellbeing, restorative and administrative undertakings capacities. Dr. Tursi will likewise get to be Chief Medical Officer of Aralez Pharmaceuticals upon the expected business mix among Aralez, POZEN and Tribute Pharmaceuticals Canada Inc. He will assume a discriminating part in the arranged readiness of the re-accommodation of the YOSPRALA™ New Drug Application (NDA) in the United States, the Marketing Authorization Application (MAA) for YOSPRALA in Europe and the New Drug Submissions (NDS) for YOSPRALA and MT400 to Health Canada. Dr. Tursi will likewise serve on the official administration group. Dr. John G. Fortress will serve as Chief Scientific Advisor until the center of one year from now.

Notes to the Stakeholders:

This article is the intellectual property of The purpose of penning down this article has been just to share information. Moreover, it is firmly believed that all the information that are revealed in this article are from reliable sources, however, we do not make any representations or warranties whatsoever of any kind, express or implied, as far as the completeness, accurateness, or reliability with respect to this article is concerned.

All the respectable visitors to this website are kindly advised to conduct their own independent research into individual stocks prior to making a purchase decision.

This article contains an advanced information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as statements regarding the forseeable frequent growth of the market for the corporation’s products, the corporation’s capability to fund its capital requirement in the close-to term and in the long term; pricing pressures; etc.

Furthermore, any statement that expresses or involves discussions with respect to forecast, expectations, beliefs, strategy, projection, objectives, aims, assumption, or future events or performance may be forward looking statements. In addition, the forward-looking statements are wholly and solely based upon expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. An easy way to identify the forward looking statements is through the use of such words as be expecting, will, foresee, guess, considered, or by statements that indicates certain actions may, could, should/might occur.


About the Author

Kristen Rose
University graduate with a bachelor's degree in business administration. Kristen is the Finance Editor, overseeing markets, economics, wealth, fintech, banking, and regulation coverage, based in London. She like to keep things simple, enjoy life, & appreciate everything around me.♡